ZA200208257B - Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis. - Google Patents

Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis. Download PDF

Info

Publication number: ZA200208257B
Authority: ZA; South Africa
Prior art keywords: alkyl; substituted; group; unsubstituted; aryl
Prior art date: 2000-04-14

Application number

ZA200208257A

Other languages

English (en)

Inventor

Theodore O Johnson Jr

Ye Hua

Hiep T Luu

Peter S Dragovich

Original Assignee

Agouron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-14

Filing date

2002-10-14

Publication date

2003-07-25

2002-10-14 Application filed by Agouron Pharma filed Critical Agouron Pharma

2003-07-25 Publication of ZA200208257B publication Critical patent/ZA200208257B/en

Links

150000001875 compounds Chemical class 0.000 title claims description 158
239000000203 mixture Substances 0.000 title description 14
238000003786 synthesis reaction Methods 0.000 title description 7
230000015572 biosynthetic process Effects 0.000 title description 5
239000000463 material Substances 0.000 title description 3
125000000217 alkyl group Chemical group 0.000 claims description 635
229910052799 carbon Inorganic materials 0.000 claims description 431
-1 nitro, amino Chemical group 0.000 claims description 299
125000001424 substituent group Chemical group 0.000 claims description 275
125000003118 aryl group Chemical group 0.000 claims description 254
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 227
125000000753 cycloalkyl group Chemical group 0.000 claims description 206
125000001072 heteroaryl group Chemical group 0.000 claims description 176
125000003545 alkoxy group Chemical group 0.000 claims description 129
125000005843 halogen group Chemical group 0.000 claims description 113
125000004429 atom Chemical group 0.000 claims description 87
229910052739 hydrogen Inorganic materials 0.000 claims description 75
125000001188 haloalkyl group Chemical group 0.000 claims description 68
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 67
125000002252 acyl group Chemical group 0.000 claims description 59
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 55
229910052717 sulfur Inorganic materials 0.000 claims description 52
125000004438 haloalkoxy group Chemical group 0.000 claims description 37
125000003441 thioacyl group Chemical group 0.000 claims description 36
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
125000001624 naphthyl group Chemical group 0.000 claims description 33
125000003282 alkyl amino group Chemical group 0.000 claims description 32
125000004663 dialkyl amino group Chemical group 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 30
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 29
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 29
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 28
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 28
125000004414 alkyl thio group Chemical group 0.000 claims description 25
125000005530 alkylenedioxy group Chemical group 0.000 claims description 24
125000004093 cyano group Chemical group *C#N 0.000 claims description 24
239000002207 metabolite Substances 0.000 claims description 24
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
239000000651 prodrug Substances 0.000 claims description 24
229940002612 prodrug Drugs 0.000 claims description 24
125000004104 aryloxy group Chemical group 0.000 claims description 23
125000001041 indolyl group Chemical group 0.000 claims description 23
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 23
239000012453 solvate Substances 0.000 claims description 23
125000003710 aryl alkyl group Chemical group 0.000 claims description 22
125000005842 heteroatom Chemical group 0.000 claims description 22
229930195734 saturated hydrocarbon Natural products 0.000 claims description 22
125000005110 aryl thio group Chemical group 0.000 claims description 21
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 21
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
125000004076 pyridyl group Chemical group 0.000 claims description 18
238000000034 method Methods 0.000 claims description 17
125000000168 pyrrolyl group Chemical group 0.000 claims description 17
229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 16
125000003277 amino group Chemical group 0.000 claims description 15
229930194542 Keto Natural products 0.000 claims description 12
241001144416 Picornavirales Species 0.000 claims description 12
125000000468 ketone group Chemical group 0.000 claims description 12
125000000842 isoxazolyl group Chemical group 0.000 claims description 11
125000001544 thienyl group Chemical group 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
125000005323 thioketone group Chemical group 0.000 claims description 9
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
230000002401 inhibitory effect Effects 0.000 claims description 8
108091005804 Peptidases Proteins 0.000 claims description 6
239000004365 Protease Substances 0.000 claims description 6
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
125000003396 thiol group Chemical class [H]S* 0.000 claims description 6
125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims description 5
125000005094 alkyl carbonyl amino alkyl group Chemical group 0.000 claims description 5
125000000000 cycloalkoxy group Chemical group 0.000 claims description 5
125000003106 haloaryl group Chemical group 0.000 claims description 5
125000000547 substituted alkyl group Chemical group 0.000 claims description 5
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 5
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 4
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 4
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
125000005368 heteroarylthio group Chemical group 0.000 claims description 4
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
101150018425 Cr1l gene Proteins 0.000 claims description 3
125000004670 alkyl amino thio carbonyl group Chemical group 0.000 claims description 3
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
125000004647 alkyl sulfenyl group Chemical group 0.000 claims description 3
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 3
125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 3
125000001769 aryl amino group Chemical group 0.000 claims description 3
125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 3
125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 3
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 3
125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 3
238000004113 cell culture Methods 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 3
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 3
125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims description 3
125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 3
125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 claims description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 claims description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
125000005241 heteroarylamino group Chemical group 0.000 claims description 3
125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 3
125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 3
125000005204 heteroarylcarbonyloxy group Chemical group 0.000 claims description 3
125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 3
125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims description 2
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
229910052792 caesium Inorganic materials 0.000 claims description 2
125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims 18
KZOWNALBTMILAP-JBMRGDGGSA-N ancitabine hydrochloride Chemical compound Cl.N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 KZOWNALBTMILAP-JBMRGDGGSA-N 0.000 claims 5
238000003556 assay Methods 0.000 claims 2
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
102100033668 Cartilage matrix protein Human genes 0.000 claims 1
101001018382 Homo sapiens Cartilage matrix protein Proteins 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
229910004734 Oy H Inorganic materials 0.000 claims 1
102100028651 Tenascin-N Human genes 0.000 claims 1
101710087911 Tenascin-N Proteins 0.000 claims 1
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000003981 vehicle Substances 0.000 claims 1
150000003254 radicals Chemical class 0.000 description 35
150000002430 hydrocarbons Chemical class 0.000 description 19
108010091324 3C proteases Proteins 0.000 description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
239000001257 hydrogen Substances 0.000 description 8
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
229910052736 halogen Inorganic materials 0.000 description 6
150000002367 halogens Chemical class 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 5
241000700605 Viruses Species 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
108010005843 Cysteine Proteases Proteins 0.000 description 4
102000005927 Cysteine Proteases Human genes 0.000 description 4
150000001204 N-oxides Chemical class 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
238000011282 treatment Methods 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
241000430519 Human rhinovirus sp. Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
201000009240 nasopharyngitis Diseases 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
125000001786 isothiazolyl group Chemical group 0.000 description 2
230000035800 maturation Effects 0.000 description 2
239000001301 oxygen Chemical group 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102100035087 Ectoderm-neural cortex protein 1 Human genes 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000709691 Enterovirus E Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 1
101000877456 Homo sapiens Ectoderm-neural cortex protein 1 Proteins 0.000 description 1
241000699727 Human echovirus Species 0.000 description 1
241001207270 Human enterovirus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000015429 Mirabilis expansa Nutrition 0.000 description 1
244000294411 Mirabilis expansa Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710134866 Quinone reductase Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010039105 Rhinoviral infections Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108700010756 Viral Polyproteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000013461 design Methods 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
125000005347 halocycloalkyl group Chemical group 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
125000005980 hexynyl group Chemical group 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000011572 manganese Substances 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000013536 miso Nutrition 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

ZA200208257A 2000-04-14 2002-10-14 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis. ZA200208257B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19779600P	2000-04-14	2000-04-14
US19849700P	2000-04-18	2000-04-18

Publications (1)

Publication Number	Publication Date
ZA200208257B true ZA200208257B (en)	2003-07-25

Family

ID=26893177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200208257A ZA200208257B (en)	2000-04-14	2002-10-14	Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis.

Country Status (19)

Country	Link
US (3)	US6610730B2 (pt)
EP (1)	EP1274682A2 (pt)
JP (1)	JP2003531139A (pt)
KR (1)	KR20030019350A (pt)
CN (1)	CN1431995A (pt)
AR (1)	AR028338A1 (pt)
AU (1)	AU2001251639A1 (pt)
BR (1)	BR0110077A (pt)
CA (1)	CA2406475A1 (pt)
HU (1)	HUP0300928A3 (pt)
IL (1)	IL152243A0 (pt)
MX (1)	MXPA02010195A (pt)
PA (1)	PA8515201A1 (pt)
PE (1)	PE20011277A1 (pt)
PL (1)	PL365198A1 (pt)
SV (1)	SV2001000379A (pt)
UY (1)	UY26666A1 (pt)
WO (1)	WO2001079167A2 (pt)
ZA (1)	ZA200208257B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7064211B2 (en) *	2002-03-22	2006-06-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof
US7192972B2 (en)	2002-03-22	2007-03-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof
CA2550515A1 (en) *	2003-12-31	2005-07-21	Taigen Biotechnology	Protease inhibitors
US7462594B2 (en) *	2003-12-31	2008-12-09	Taigen Biotechnology Co., Ltd.	Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
KR100891699B1 (ko)	2007-04-10	2009-04-03	광주과학기술원	7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
ES2960114T3 (es)	2008-01-25	2024-02-29	Specialty Operations France	Uso de esteramidas, nuevas esteramidas y procedimiento para preparar esteramidas
US8450500B2 (en)	2008-06-04	2013-05-28	Synta Pharmaceuticals Corp.	Pyrrole compounds that modulate HSP90 activity
EP3733672B1 (en)	2017-12-25	2023-03-22	Sumitomo Chemical Company, Limited	Heterocyclic compounds and noxious arthropod control agent containing same
WO2021252491A1 (en)	2020-06-10	2021-12-16	Aligos Therapeutics, Inc.	Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2022156692A1 (zh) *	2021-01-22	2022-07-28	中国人民解放军军事科学院军事医学研究院	一种环肽类病毒蛋白酶抑制剂，其制备方法，及其在抗病毒药物中的应用
KR20240035513A (ko)	2021-07-09	2024-03-15	알리고스 테라퓨틱스 인코포레이티드	항바이러스 화합물
US12065428B2 (en)	2021-09-17	2024-08-20	Aligos Therapeutics, Inc.	Anti-viral compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5374623A (en)	1992-08-20	1994-12-20	Prototek, Inc.	Cysteine protease inhibitors effective for in vivo use
US5486623A (en)	1993-12-08	1996-01-23	Prototek, Inc.	Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en)	1994-02-25	1995-05-26	Khepri Pharmaceuticals Inc	Novel cysteine protease inhibitors
IT1269511B (it)	1994-05-17	1997-04-01	Univ Degli Studi Milano	Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5523312A (en) *	1994-09-27	1996-06-04	Sterling Winthrop Inc.	Antipicornaviral agents
US5498616A (en)	1994-11-04	1996-03-12	Cephalon, Inc.	Cysteine protease and serine protease inhibitors
AU5122196A (en) *	1995-03-31	1996-10-16	Takeda Chemical Industries Ltd.	Cysteine protease inhibitor
US5856530A (en)	1996-05-14	1999-01-05	Agouron Pharmaceuticals, Inc.	Antipicornaviral compounds and methods for their use and preparation
DE69733137T2 (de) *	1996-05-14	2006-03-02	Agouron Pharmaceuticals, Inc., San Diego	Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
WO1997049668A1 (en)	1996-06-13	1997-12-31	Smithkline Beecham Corporation	Inhibitiors of cysteine protease
GB9615692D0 (en) *	1996-07-25	1996-09-04	Pharmacia Spa	Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
US6020371A (en)	1997-03-28	2000-02-01	Agouron Pharmaceuticals, Inc.	Antipicornaviral compounds compositions containing them and methods for their use
US6331554B1 (en)	1997-03-28	2001-12-18	Agouron Pharmaceuticals, Inc.	Antipicornaviral compounds, compositions containing them, and methods for their use
ES2206907T3 (es)	1997-03-28	2004-05-16	Agouron Pharmaceuticals, Inc.	Compuestos anti-picornavirus, composiciones que contienen estos compuestos y sus procedimientos de utilizacion.
US5962487A (en)	1997-12-16	1999-10-05	Agouron Pharmaceuticals, Inc.	Antipicornaviral compounds and methods for their use and preparation
KR20010043004A (ko) *	1998-04-30	2001-05-25	개리 이. 프라이드만	피코르나 바이러스 억제 화합물, 그의 제조 방법 및 용도
US6369226B1 (en)	1999-06-21	2002-04-09	Agouron Pharmaceuticals, Inc.	Substituted benzamide inhibitors of rhinovirus 3C protease
KR20020025964A (ko) *	1999-08-04	2002-04-04	개리 이. 프라이드만	피코르나바이러스 억제 화합물 및 조성물, 그의 약학적용도, 및 그의 합성용 물질
EP1206470A2 (en)	1999-08-24	2002-05-22	Agouron Pharmaceuticals, Inc.	Processes and intermediates for the preparation of isoxazolecarboxamides and analogues
PE20010517A1 (es)	1999-08-24	2001-05-16	Agouron Pharma	Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
PE20020157A1 (es)	1999-12-03	2002-02-22	Agouron Pharma	Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis
HUP0301331A3 (en) *	2000-06-14	2004-03-01	Agouron Pharmaceuticals Inc La	Antipicornaviral compounds process for their preparation and compositions containing them, their pharmaceutical uses, and intermediates for their synthesis

2001
- 2001-04-11 PA PA20018515201A patent/PA8515201A1/es unknown
- 2001-04-11 PE PE2001000336A patent/PE20011277A1/es not_active Application Discontinuation
- 2001-04-12 EP EP01925037A patent/EP1274682A2/en not_active Withdrawn
- 2001-04-12 CN CN01810359A patent/CN1431995A/zh active Pending
- 2001-04-12 CA CA002406475A patent/CA2406475A1/en not_active Abandoned
- 2001-04-12 BR BR0110077-7A patent/BR0110077A/pt not_active IP Right Cessation
- 2001-04-12 JP JP2001576769A patent/JP2003531139A/ja active Pending
- 2001-04-12 KR KR1020027013804A patent/KR20030019350A/ko not_active Application Discontinuation
- 2001-04-12 WO PCT/US2001/012333 patent/WO2001079167A2/en not_active Application Discontinuation
- 2001-04-12 IL IL15224301A patent/IL152243A0/xx unknown
- 2001-04-12 US US09/834,783 patent/US6610730B2/en not_active Expired - Fee Related
- 2001-04-12 MX MXPA02010195A patent/MXPA02010195A/es unknown
- 2001-04-12 HU HU0300928A patent/HUP0300928A3/hu unknown
- 2001-04-12 AU AU2001251639A patent/AU2001251639A1/en not_active Abandoned
- 2001-04-12 PL PL01365198A patent/PL365198A1/xx not_active Application Discontinuation
- 2001-04-16 UY UY26666A patent/UY26666A1/es unknown
- 2001-04-17 SV SV2001000379A patent/SV2001000379A/es not_active Application Discontinuation
- 2001-04-17 AR ARP010101775A patent/AR028338A1/es not_active Application Discontinuation
2002
- 2002-10-14 ZA ZA200208257A patent/ZA200208257B/en unknown
2003
- 2003-05-12 US US10/435,082 patent/US6872745B2/en not_active Expired - Fee Related
2004
- 2004-11-12 US US10/986,109 patent/US20050101651A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0300928A3 (en)	2005-08-29
US20030225042A1 (en)	2003-12-04
PL365198A1 (en)	2004-12-27
MXPA02010195A (es)	2003-04-25
US20020006943A1 (en)	2002-01-17
WO2001079167A3 (en)	2002-02-28
CA2406475A1 (en)	2001-10-25
US20050101651A1 (en)	2005-05-12
SV2001000379A (es)	2001-10-16
US6610730B2 (en)	2003-08-26
IL152243A0 (en)	2003-05-29
UY26666A1 (es)	2001-11-30
HUP0300928A2 (hu)	2003-08-28
EP1274682A2 (en)	2003-01-15
JP2003531139A (ja)	2003-10-21
CN1431995A (zh)	2003-07-23
KR20030019350A (ko)	2003-03-06
US6872745B2 (en)	2005-03-29
AR028338A1 (es)	2003-05-07
PA8515201A1 (es)	2002-10-24
AU2001251639A1 (en)	2001-10-30
WO2001079167A2 (en)	2001-10-25
BR0110077A (pt)	2003-06-17
PE20011277A1 (es)	2002-01-07

Publication	Publication Date	Title
ZA200208257B (en)	2003-07-25	Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis.
US10611748B2 (en)	2020-04-07	Xanthone derivatives for the treatment of hepatitis B virus disease
DE69512797D1 (en)	1999-11-18	Prostaglandin-synthase hemmer
CA2952541A1 (en)	2016-02-18	Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
CA2948080A1 (en)	2015-11-19	Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
MXPA02006671A (es)	2002-10-23	Procedimiento para preparar derivados del acido 3-hidroxipicolinico.
DE69501947D1 (de)	1998-05-07	SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
LU92824I2 (fr)	2015-11-24	Ceritinib ou un sel pharmaceutiquement acceptable de celui-ci
ME02702B (me)	2017-10-20	Postupci za pripremu inhibitora sgl t2
JP2004500347A5 (pt)	2008-03-13
MX2010013773A (es)	2011-01-21	Compuestos de 2,4'-bipiridinilo como inhibidores de cinasa d de proteina utiles para el tratamiento de, entre otras, insuficiencia cardiaca ia y cancer.
EA200200774A1 (ru)	2003-02-27	Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
IT1230859B (it)	1991-11-08	2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
DK221882A (da)	1982-11-19	Fremgangsmaade til fremstilling af oxobenzoxaziner
PL378201A1 (pl)	2006-03-20	Sposób farmaceutyczny oraz związki wytwarzane tym sposobem
NO974513L (no)	1997-09-29	Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling
AU3749495A (en)	1996-05-06	Diazepino-indoles as phosphodiesterase iv inhibitors
TW200611916A (en)	2006-04-16	High molecular compound, positive type resist composition and process for forming resist pattern
DE69005974D1 (de)	1994-02-24	Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
JP7569433B2 (ja)	2024-10-17	抗ウイルス剤としてのピロリジンメインプロテアーゼ阻害剤
HRP20000027B1 (en)	2006-07-31	Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds
EA200400470A1 (ru)	2004-08-26	Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
JP2004503533A (ja)	2004-02-05	抗ピコルナウイルス化合物及び組成物、その医薬的使用、並びにその合成のための物質
Wang et al.	1999	A Novel Synthesis of Thieno [2, 3-C] pyrazole
FR2823749B1 (fr)	2004-02-20	Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant